Chemaxon blog
Filter by content type
Ending the game of cat and mouse: The rise of structure-based generic definitions in Controlled Compound Legislation
Discover how the surge in generic drug legislation complicates identification of controlled...
Pharma use case with Design Hub: Digital workflow support for compound design
Design Hub case study - use case with a renowned German pharmaceutical company.
Lunch and Learn 2024
Join our India Lunch and Learn events with presentations and Chemaxon product demos in May.
ChemTalks 2024
ChemTalks is asking the question: how can technology bridge silos within drug discovery? Join us...
Discovery Europe 2024
Join us at the Discovery Europe event in Basel, Switzerland and engage with our experts about...
Chemical Data Migration best practices - Stage 4: Post-Migration Validation and Support
Maximize the value of your chemical data migration project. Explore the crucial stage of...
Chemical Data Migration best practices - Stage 3: Data Migration
Navigate the complexities of chemical data migration, from planning to production. Explore...
Improving Your Drug Discovery Workflow: Collaboration, Data Management, and Security
PPT administration is tedious and unreliable. How to keep track of drug discovery projects...
Roadblocks of DMTA project success - and how to eliminate them
Discover how to navigate complex challenges in your DMTA projects - make informed compound...
"Make the company look like I won the lottery"
This article was originally published in Hungarian, in November 2023. Visit Publication Chemaxon...
Why Are Medicinal Chemists Reluctant to Use AI/ML Tools?
There is a lot of current chatter about how AI/ML tools like ChatGPT will soon take over several...
Overcoming Medicinal Chemists’ Reluctance to Use AI/ML Tools
AI/ML tools in drug discovery, concerns about data quality and availability, interpretability of...